logo
These birds carry a toxin deadlier than cyanide

These birds carry a toxin deadlier than cyanide

New Guinea is home to some of the world's most toxic birds. Why they contain poison, and how they withstand the it is still a source of scientific mystery. The variable pitohui, a poisonous bird, captured in mist net on the outskirts of Wanang Village in Papua New Guinea in 2018. Photographs By Knud Jønsson
In the summer of 1989, Jack Dumbacher was a fresh-faced ornithologist-in-training on his maiden expedition to the lush rainforests of Papua New Guinea. One sticky afternoon, he noticed an unusual bird with gaudy black-and-orange feathers entangled in his mist nets. But as Dumbacher tried to set it free, the hooded pitohui scratched him.
'They're jay-sized birds with needle-sharp claws and bills,' says Dumbacher, who instinctively put the cut to his lips. 'My mouth started to tingle and burn, and then went numb, lasting until the night.'
When Dumbacher consulted his local guides, they nodded knowingly, telling him how villagers would avoid the 'rubbish birds,' eating them only if they were 'skinned and specially prepared.' Curiosity piqued, the then-graduate student at the University of Chicago spent the next year collecting pitohui samples and searching for a chemist back home who could pinpoint the source of the peculiar sensations.
In 1992, Dumbacher and his collaborators announced their astonishing findings: hooded pitohuis carry batrachotoxin. The toxin is deadlier than cyanide and is among the most lethal substances in the animal kingdom. It's the same substance found in certain poison dart frogs halfway round the world.
Since then, at least a dozen other avian species, out of more than 10,500 known to science, have been identified as toxic. Some members of this select group—such as the European quail, North American ruffed grouse, and European hoopoes —are found outside of New Guinea and contain different toxins. The majority, however, are batrachotoxin-carrying and endemic to the world's second largest island, including at least five other pitohui species and the blue-capped ifrit.
But 35 years on from Dumbacher's serendipitous discovery, much remains a mystery about New Guinea's poisonous birds. 'There's a ton that we don't know—from the ecology of the birds to how they use batrachotoxin for defense and where they get it from,' says Dumbacher, now California Academy of Sciences' curator of birds and mammals.
He last visited the island in 2011, and another team of scientists—led by ecologist Knud Jønsson from the Swedish Museum of Natural History and evolutionary and community biologist Kasun Bodawatta at the University of Copenhagen—are continuing Dumbacher's research. Already, they've made inroads, identifying two new toxic bird species in 2023, the first discovery in nearly two decades. They plan to visit Papua New Guinea annually until 2028.
They hope to answer a key question: where does the toxin—believed to protect the birds from predators and parasites—come from?
One theory for the origin of this poison is the birds' diet.
'It's been put forth that they eat these Choresine beetles and that's how they get their toxin,' says Jønsson. 'But in reality, we don't know.'
Dumbacher—who, in 2004, was the first to describe how batrachotoxin is present in both birds and beetles—doesn't believe the toxin originates in the tiny rice-sized insects.
'Most of the information suggests that beetles can't produce such steroidal alkaloids,' he says. 'So it's very possible that the beetles are getting it from some other source like soil mites or even a plant.'
To track batrachotoxin's origin, the researchers plan to collect poisonous birds and compare their stomach contents to insects caught in nearby traps. 'The idea is to try and home in on potential prey items that have the toxin,' explains Jønsson. 'It's very much looking for a needle in a haystack, but that's the very first step that we can take.'
They've also teamed up with Christine Beemelmanns, a chemist at Germany's Saarland University to pinpoint batrachotoxin and molecularly similar toxins in the samples already collected.
Tests have shown that poisonous birds contain a mixture of toxic derivatives—Beemelmanns' lab has identified six so far—which can vary in concentration between individuals and species. The hooded pitohui is one of several poisonous birds that have been documented in Papua New Guinea. While poisonous birds have been documented in North America and Europe, the majority known to science are found in the this South Pacific region. Photographs By Knud Jønsson How do birds remain immune?
Another enduring mystery is how the birds protect themselves from the deadly toxin they carry.
Batrachotoxin binds to sodium ion channels in nerve, muscle, and heart cells, resulting in numbness, convulsions, paralysis, and even death. 'It sits on these channels and keeps them open, so the nerves just go on twitching,' says Jønsson.
Poisonous birds contain far less toxin than the golden poison frog, which carries enough batrachotoxin to kill 10 grown men. The hooded pitohui—the most toxic avian species—isn't lethal when handled or consumed.
The longstanding theory that explains how the birds 'aren't killing themselves' is that they, like poison dart frogs, contain mutations in their sodium channels, which prevents the toxin from binding, says Daniel Minor, a biophysicist at the University of California, San Francisco, who's not involved with Jønsson and Bodawatta's upcoming research expeditions.
The same trait is found in the fugu pufferfish, blue-ringed octopus, and other poisonous animals that remain impervious to the toxins they carry.
Indeed, when Jønsson and his collaborators compared the genomes of six toxic bird species with their non-toxic cousins within the same families, they discovered that poisonous birds contained multiple mutations in a gene encoding a specific sodium channel.
However, when Minor's team conducted electrophysiological tests on genes cloned from the southern variable pitohui in a separate set of experiments, they 'were distraught' to discover that the sodium channels remained sensitive to batrachotoxin—despite their mutations.
Minor now believes that the birds' resistance lies in an as-yet-unidentified protein which acts as a 'toxin sponge,' binding to batrachotoxin and sequestering it. He and his colleagues' work on saxitoxin, another protein that binds to sodium channels, provided this insight.
'Our lab showed that saxiphilin, a protein found naturally in poison dart frogs, can scoop in and bind to saxitoxin with high affinity,' he explains. 'So maybe it's the same for batrachotoxin.'
Jønsson and Bodawatta think the two mechanisms might be complementary. 'Birds, anyway, need to transport batrachotoxin from the gut to the skin,' says Bodawatta. 'So they must have a transporter protein that facilitates this.' Are there more?
Scientists' are keen to know whether more toxic birds exist.
Jønsson thinks it's highly likely. "New Guinea's poisonous birds belong to the Corvides super-family of birds, which comprise roughly 700 species worldwide,' he says. New Guinea is home to 140 of them, and his team has so far studied just a fifth of them.
Starting this November, his team will collect 'as many Corvides samples as possible' from different parts of the island and screen them for batrachotoxin. They also plan to sequence as least one individual per species to identify sodium channel mutations.
A more comprehensive genomic dataset will also allow scientists to identify possible toxin sponge proteins, adds Bodawatta.
More broadly, the researchers want to study 'the super cool and crazy convergent evolution' that's allowed for this special toxin resistance in both frogs and birds, as well as unrelated avian species within New Guinea and elsewhere in the world, Bodawatta says.
'Understanding convergent adaptations by natural selection is a central goal in evolutionary biology,' adds Jønsson.
The more scientists learn about what exists, the more questions they'll be able to ask about why they do.
'Maybe in two to three years, we'll have some new insights to share,' says Bodawatta. 'This is just the beginning.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress
Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress

Yahoo

timean hour ago

  • Yahoo

Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress

UPPSALA, SE / / June 10, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces financial goals for the upcoming two fiscal years. The targets reflect the company's recent commercial momentum and its long-term commitment to transparency and value creation for patients, healthcare providers, and shareholders. The recently communicated partner agreement with Tempus AI in the U.S. and the agreement with a leading healthcare provider, which was communicated in December 2024, are expected to generate significant revenues for Biovica. Along with more than 15 active collaborations with pharmaceutical companies representing a total project value of approximately 25 MSEK and the 18 active partnership agreements covering key European markets, the company has established a strong foundation for growth. On this basis, Biovica is now in a position to provide clear financial guidance. Biovica's financial targets: FY 2024/25 (ending April 30, 2025): Net sales of SEK 8.5 million FY 2025/26: Net sales of SEK 50 million FY 2026/27: Net sales of SEK 150 million With expected operating expenses at the current level of approximately 90 MSEK per year, Biovica anticipates becoming cash-flow positive during the third quarter of FY 2026/27. The expected distribution of revenues during FY25/26 and FY 26/27 are: 65% from the U.S. market, driven by reimbursement and volume growth through strategic partnerships 30% from pharma services, based on ongoing and future biomarker collaborations 5% from European partners, through distributor and lab agreements across 18 territories "These targets reflect the solid groundwork we have laid over the past years," says Anders Rylander, CEO of Biovica. "We've achieved clinical validation through world-leading oncologists and institutions, received FDA clearance, established a CMS/Medicare price, initiated commercial sales, and now secured strategic partnerships that enable us to scale up. The pieces are in place to deliver on our vision-improving outcomes for patients, optimizing care for providers, and generating long-term value for shareholders." Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-10 18:31 CEST. Attachments Biovica announces financial targets following key partnerships and commercial progress SOURCE: Biovica International View the original press release on ACCESS Newswire

Get Ready to Hear a Lot More About Your Mitochondria
Get Ready to Hear a Lot More About Your Mitochondria

Yahoo

time2 hours ago

  • Yahoo

Get Ready to Hear a Lot More About Your Mitochondria

The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here. Robert F. Kennedy Jr.'s warning about mitochondria slipped in between the anti-vaccine junk science and the excoriation of pharmaceutical drugs as 'the No. 3 killer in our country.' He was speaking in 2023 to Joe Rogan, elaborating on the dangers of Wi-Fi—which no high-quality scientific evidence has shown to harm anyone's health—and arguing that it causes disease by somehow opening the blood-brain barrier, and by degrading victims' mitochondria. The mention of mitochondria—the tiny structures that generate energy within our cells—was brief. Two years later, mitochondrial health is poised to become a pillar of the MAHA movement, already showing up in marketing for supplements and on podcasts across the 'manosphere.' Casey Means, President Donald Trump's newest nominee for surgeon general, has singled out the organelle as the main casualty of the modern American health crisis. According to Means (who has an M.D. but no active medical license), most of America's chronic ailments can be traced to mitochondrial dysfunction. Should she be confirmed to the post of surgeon general, the American public can expect to hear a lot more about mitochondria. Among scientists, interest and investment in mitochondria have risen notably in the past five years, Kay Macleod, a University of Chicago researcher who studies mitochondria's role in cancer, told me. Mitochondria, after all, perform a variety of crucial functions in the human body. Beyond powering cells, they can affect gene expression, help certain enzymes function, and modulate cell death, Macleod said. When mitochondria are defective, people do indeed suffer. Vamsi Mootha, a mitochondrial biologist based at Massachusetts General Hospital and the Broad Institute, told me that rare genetic defects (appearing in about one in 4,300 people) can cause the organelles to malfunction, leading to muscle weakness, heart abnormalities, cognitive disability, and liver and kidney problems. Evidence also suggests that defects in mitochondria directly contribute to symptoms of Parkinson's disease, and could be both a cause and an effect of type 2 diabetes. Other conditions' links to mitochondria are blurrier. Researchers see aberrant mitochondria in postmortem biopsies of patients with illnesses such as Alzheimer's, cancer, and fatty-liver disease, Mootha said; whether those damaged mitochondria cause or result from such conditions is not yet clear. But according to Good Energy, the book Means published last year with a top MAHA adviser—her brother, Calley—mitochondrial dysfunction is a veritable plague upon the United States, responsible for both serious illness and everyday malaise. In their view, modern Western diets and lifestyles wreck countless Americans' metabolic health: Every time you drink unfiltered water or a soda, or feel the stress of mounting phone notifications, you hurt your mitochondria, they say, triggering an immune response that in turn triggers inflammation. (Damaged mitochondria really can cause inflammation, Macleod said.) This chain of events, the Meanses claim, can be blamed for virtually every common chronic health condition: migraines, depression, infertility, heart disease, obesity, cancer, and more. (Casey Means did not respond to requests for comment; reached by email, Calley did not respond to my questions about mitochondria, but noted, 'There is significant scientific evidence that healthy food, exercise and sleep have a significant impact on reversing chronic disease.') Good Energy follows a typical wellness playbook: using a mixture of valid and dubious research to pin a slew of common health problems on one overlooked element of health—and advertising a cure. Among the culprits for our mitochondrial ravaging, according to the Meanses, are poor sleep, medications, ultraprocessed foods, seed oils, too many calories, and too few vitamins, as well as chronically staying in comfortable ambient temperatures. The Means siblings therefore recommend eschewing refined sugar in favor of leafy greens, avoiding nicotine and alcohol, frequenting saunas and cold plunges, getting seven to eight hours of uninterrupted sleep a night, and cleansing your life of environmental toxins. Some studies indeed suggest that mitochondrial function is linked with sleep and temperature, but they've all been conducted on cell cultures, organoids, or mice. According to Macleod, evidence suggests that diet, too, is likely important. But only one lifestyle intervention—exercise—has been definitively shown to improve mitochondrial health in humans. The Meanses are riding a wave of interest in mitochondrial health in the wellness world. Earlier this year, the longevity influencer Bryan Johnson and the ivermectin enthusiast Mel Gibson both endorsed the dye methylene blue for its power to improve mitochondrial respiration; Kennedy was filmed slipping something that looks a lot like methylene blue into his drink. (Kennedy did not respond to a request for comment; the FDA has approved methylene blue, but only as a treatment for the blood disease methemoglobinemia.) AG1, formerly known as Athletic Greens, formulates its drinkable vitamins for mitochondrial health. Even one laser-light skin treatment promises to 'recharge failing mitochondria.' The enzyme CoQ10 is popular right now as a supplement for mitochondrial function, as is NAD, a molecule involved in mitochondria's production of energy. NAD IV drips are especially beloved by celebrities such as Gwyneth Paltrow, Kendall Jenner, and the Biebers. These supplements are generally thought to be safe, and some preliminary research shows that NAD supplementation could help patients with Parkinson's or other neurodegenerative diseases, and that CoQ10 could benefit people with mitochondrial disorders. Patients whose symptoms are clearly caused or made worse by deficiencies in a specific vitamin, such as thiamine, can benefit from supplementing those vitamins, Mootha said. But little research explores how these supplements might affect healthy adults. [Read: The MAHA takeover is complete] In Good Energy, as well as on her website and in podcast appearances, Casey Means promotes a number of supplements for mitochondrial health. She also recommends that people wear continuous glucose monitors—available from her company, Levels Health, for $184 a month—to help prevent overwhelming their mitochondria with too much glucose. (According to Macleod, glucose levels are only 'a very indirect measure' of mitochondrial activity.) As with so many problems that wellness influencers harp on, the supposed solution to this one involves buying products from those exact same people. At best, all of this attention to mitochondria could lead Americans to healthier habits. Much of the advice in Good Energy echoes health recommendations we've all heard for decades; getting regular exercise and plenty of fiber is good guidance, regardless of anyone's reasons for doing so. Switching out unhealthy habits for healthy ones will likely even improve your mitochondrial health, Jaya Ganesh, a mitochondrial-disease expert at Icahn School of Medicine at Mount Sinai, told me. After all, 'if you consistently beat your body up with unhealthy habits, everything is going to fall sick,' Ganesh said. But the mitochondrial approach to wellness carries risks, too. For patients with genetically caused mitochondrial disease, lifestyle changes might marginally improve some symptoms, Ganesh said, but attempting to cure such conditions with supplements and a healthy diet alone could be dangerous. Means also calls out medications—including antibiotics, chemotherapy, antiretrovirals, statins, and high-blood-pressure drugs—for interfering with mitochondria. Macleod told me that statins really do affect mitochondria, as do some antibiotics. (The latter makes sense: Mitochondria are thought to have evolved from bacteria more than a billion years ago.) That's no reason, though, to avoid any of these medications if a doctor has determined that you need them. [Read: America can't break its wellness habit] And yet, a whole chapter of Good Energy is dedicated to the idea that readers should mistrust the motives of their doctors, who the authors say profit by keeping Americans sick. The book is less critical of the ways the wellness industry preys on people's fears. Zooming in on mitochondria might offer a reassuringly specific and seemingly scientific explanation of the many real ills of the U.S. population, but ultimately, Means and MAHA are only helping obscure the big picture. Article originally published at The Atlantic

When is the next full moon? June's Strawberry Moon rises Tuesday night
When is the next full moon? June's Strawberry Moon rises Tuesday night

Yahoo

time2 hours ago

  • Yahoo

When is the next full moon? June's Strawberry Moon rises Tuesday night

Ready to see a cosmic phenomenon in the night sky? There's a full moon rising tonight, and it won't be regular. June's Strawberry Moon will be different celestial event that won't be seen again until 2043. According to it will be the lowest laying full moon seen north of the equator, as well as one of the farthest from the sun. Because the moon is near its farthest point from Earth, it'll appear slightly smaller and dimmer. The Strawberry Moon is the final full moon of the spring in the Northern Hemisphere that signals the coming of the summer solstice. Each full moon name derives from natural event occuring such as seasonal changes used by Native American, Colonial American and European sources. According to the Old Farmer's Almanac, The Strawberry Moon name comes not from its color, but from the Algonquin tribes in North America, who saw this full Moon as the signal that wild strawberries were ready for harvest. The moon will reach its peak and become full visible at 3:45 a.m. EDT on Wednesday, June 11, but the best time so see it will be as it rises on June 10, according to The moon rising occurs at different times depending on locations. Moonset in Monmouth and Ocean counties for June 10, 2025, is at 8:25 pm. All times are Eastern Daylight Time. This article originally appeared on Asbury Park Press: June 2025 full moon: How to see Strawberry Moon in New Jersey

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store